[1] Taru V, Szabo G, Mehal W, et al. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. J Hepatol,2024, 81(5):895-910.
[2] Le MH, Le DM, Baez TC, et al. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Mol Hepatol,2024,30(2):235-246.
[3] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol,2023,79(2):516-537.
[4] Phoompoung P, Herrera S, Pérez Cortés Villalobos A, et al. Risk factors of invasive fungal infections in liver transplant recipients: A systematic review and meta-analysis. Am J Transplant, 2022,22(4): 1213-1229.
[5] Ali S, Prakash S, Murali AR. Hepatic manifestations of nonhepatotropic infectious agents including severe acute respiratory syndrome coronavirus-2, adenovirus, herpes simplex virus, and coxiella burnetii, Gastroenterol Clin North Am,2021,50(2):383-402.
[6] García-Cortés M, Pinazo-Bandera JM, Lucena MI, et al. Drug-induced autoimmune-like hepatitis. Clin Liver Dis (Hoboken),2024,23(1):e0172.
[7] Alkashash A, Zhang X, Vuppalanchi R,et al. Distinction of autoimmune hepatitis from drug-induced autoimmune like hepatitis: The answer lies at the interface. J Hepatol,2024,81(1):e45-e47.
[8] 茅益民. 《中国药物性肝损伤诊治指南(2023年版)》解读. 中华肝脏病杂志,2024, 32(4): 312-317.
[9] 李会芳,宋海波,王伽伯,等. 2020年版《中国药典》一部中含栀子中成药的不良反应回顾性分析. 中成药,2022,44(7):2391-2395.
[10] Chwa K, Aung S, Reyes Yparraguirre A,et al. The autoimmune gender gap: a rare case of a male patient with overlapping autoimmune hepatitis and primary biliary cholangitis. Cureus,2024,16(6):e63312.
[11] Hussain N, Trivedi PJ. The inconvenient truth of primary biliary cholangitis/autoimmune hepatitis overlap syndrome. Clin Liver Dis,2022,26(4): 657-680.
[12] Chang ML, Le PH, Chen WT,et al. Distinct characteristics of various autoimmune liver diseases: A 22-year hospital-based study in Taiwan. J Gastroenterol Hepatol, 2024,39(12): 2835-2844. |
